Results 41 to 50 of about 1,054 (155)

In Silico Clinical Trials in Drug Development: Virtual Patients, Applications, and Regulatory Convergence

Clinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1181-1194, November 2026.
Conventional clinical trials remain the benchmark for evaluating therapeutic safety and efficacy, yet they are constrained by escalating costs, withdrawal over the extended follow‐up periods, recruitment difficulties, ethical limits, and a restricted ability to characterize heterogeneous populations.
Maximilian Balmus, Sheng‐Ya Wang, Edward W. G. Ashton, Rosie K. Barrows, Molly Monks, Yuzhang Ge, Arthur Lefebvre, Steven A. Niederer   +7 more
wiley   +1 more source

Comparing the Efficacy and Safety of Galcanezumab Versus Rimegepant for Prevention of Episodic Migraine: Results from a Randomized, Controlled Clinical Trial

Neurology and Therapy, 2023
Introduction There have been no prior trials directly comparing the efficacy of different calcitonin gene-related peptide (CGRP) antagonists for migraine prevention.
Todd J. Schwedt, Tina M. Myers Oakes, James M. Martinez, Bert B. Vargas, Hitendra Pandey, Eric M. Pearlman, Diane R. Richardson, Oralee J. Varnado, Michael Cobas Meyer, Peter J. Goadsby   +9 more
doaj   +1 more source

Framework for headache management in pediatric patients with stroke and cerebrovascular lesions: A narrative review

Headache: The Journal of Head and Face Pain, Volume 66, Issue 9, Page 2138-2155, October 2026.
Abstract Objective To present a practical, evidence‐based framework for the management of headache disorders in pediatric patients with prior stroke or underlying cerebral vascular lesions, with particular attention to safety and efficacy of pharmacologic and non‐pharmacologic therapies.
Allison C. Hyland, Samuel J. Belfer, Christine K. Fox, Samantha L. Irwin, Rachel Vassar, Ann Oh, Sruthi Ilangovan, Amy A. Gelfand   +7 more
wiley   +1 more source

First real-world study on the effectiveness and tolerability of rimegepant for acute migraine therapy in Chinese patients

The Journal of Headache and Pain
Background Rimegepant, a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist, is indicated for acute and preventive migraine treatment in the United States and other countries.
Zhao Yang, Xiaodan Wang, Mengyue Niu, Qiao Wei, Huizhu Zhong, Xiaoyan Li, Weihong Yuan, Wenli Xu, Shuo Zhu, Shengyuan Yu, Jun Liu, Jianzhou Yan, Wenyan Kang, Peijian Huang   +13 more
doaj   +1 more source

Cost-Effectiveness Analysis of Rimegepant Versus Eletriptan for Patients with Acute Episodic Migraine in Thailand: Establishing Dominance from a Societal Perspective

Siriraj Medical Journal
Objective: For acute migraine patients unresponsive to sumatriptan, the choice is between another triptan, eletriptan, and the novel CGRP antagonist, rimegepant.
Jadesada Lertsirimunkong, Wiwat Thavornwattanayong, Jidapha Pradab, Jidapa Khongbun, Kitiphong Khunphong, Nattanun Panyasrilert   +5 more
doaj   +1 more source

Cancer‐related pain: A bidirectional modulator of cancer progression

Clinical and Translational Medicine, Volume 16, Issue 9, September 2026.
CRP and tumour progression engage in a dynamic, bidirectional circuit mediated by multiple mechanisms involving neuroimmunology and cancer ‐neuroscience. Analgesic interventions may affect tumour progression, while anticancer therapies can influence pain. Targeting pain in cancer may have promising therapeutic value in cancer progression.
Junzhe He, Yu Zhang, Qian Liu, Biao Yan, Peiwei Chai, Renbing Jia   +5 more
wiley   +1 more source

Migraine: Epidemiology, Risk Factors, Pathophysiology, and Treatment

MedComm, Volume 7, Issue 9, September 2026.
Migraine is a highly prevalent, female‐predominant, and disabling brain disorder shaped by genetic susceptibility, hormonal influences, modifiable attack factors, and comorbidity‐related progression. This review integrates current evidence on migraine epidemiology, phase‐specific neurovascular and neuroglial mechanisms, including CGRP signaling and ...
Weiwei Lu, Yuan Zhang, Chen Shi, Yu Tao, Shaoxin Li, Yufang Sun, Fuhai Ji, Dongsheng Jiang, Terrance P. Snutch, Jin Tao   +9 more
wiley   +1 more source

Cancer Neuroscience: From Local Neuro–Immune Microenvironments to Systemic Brain–Body Circuitry

MedComm, Volume 7, Issue 9, September 2026.
This review outlines the cancer neuroscience paradigm, spanning systemic brain–body circuitry and local neuro–immune–tumor microenvironments. We discuss how tumors promote axonogenesis and pseudo‐synapse formation, and how sensory neuropeptides, such as CGRP, contribute to CD8+ T‐cell exhaustion.
Mingxuan Xie, Yu Zhao, Xinruo Xing, Yuqiang Liu, Jungang Zhao, Maojin Yao, Jun Tang, Jianzhu Zhao   +7 more
wiley   +1 more source

Weight loss with atogepant in the long‐term treatment of migraine: An interim analysis of a safety endpoint from a phase 3, multicenter, open‐label, 156‐week extension study

Headache: The Journal of Head and Face Pain, Volume 66, Issue 8, Page 1730-1740, September 2026.
Abstract Objective To assess weight loss with atogepant 60 mg once daily during long‐term treatment of chronic migraine (CM) and episodic migraine (EM) among participants previously failed by two to four classes of conventional oral preventive medications.
Dale S. Bond, Jonathan H. Smith, Alexandra Sinclair, Peter J. Goadsby, Jessica Ailani, Yingyi Liu, Rosa De Abreu Ferreira, Brett Dabruzzo, Joel M. Trugman, B. Lee Peterlin   +9 more
wiley   +1 more source

Piezo2 Mediates a Vicious Cycle of “Mechanical Homeostasis Imbalance—Inflammation” in Sensory Nerves and the Cartilage Endplate

Advanced Science, Volume 13, Issue 38, 9 July 2026.
In a lumbar spine instability model, dorsal root ganglion cells mediate the perception of relevant mechanical stresses through Piezo2 and subsequently release CGRP. CGRP activates the NF‐κB signaling pathway in cartilage endplate cells through the receptor RAMP1.
Hanpeng Xu, Wen Geng, Zhi Du, Yifan Du, Di Wu, Bide Tong, Huaizhen Liang, Xingyu Zhou, Zixuan Ou, Junyu Wei, Kun Wang, Yu Song, Wenbin Hua, Yan Xu, Wencan Ke, Bingjin Wang, Cao Yang   +16 more
wiley   +1 more source